Expert Opinion on Investigational Drugs · 2000 · 97 citations · 0 references
MedicinePharmacologyPharmacotherapyAntimicrobial PharmacologyChemotherapyMycologyAntifungal AgentsAntifungal PharmacologyAntifungal PharmacotherapyAntifungal ResistanceAntifungal TherapyCombination Antimicrobial TherapyAntifungal ChemotherapyAntifungal TreatmentsAntifungal-chemotherapy InteractionsCombination Antifungal TherapyNew Antifungal AgentsNovel Antifungal Drug DevelopmentNovel Antifungal TargetsPoster Presentations
The 40th ICAAC Meeting provided one of the widest varieties of new antibacterial and antifungal agents in years, with a range of improved ‘classical’ agents (Β-lactams, carbapenems), novel quinolone agents and totally new ideas for novel therapeutic intervention. Among the compounds reported were potent anti-MRSA carbapenems, novel des-fluoroquinolones (BMS 284756/T-3811), non-fluorinated quinolones, quinolone-related antibacterials, novel cephalosporins (cefditoren, RWJ-54428, MC 04546), ketolides (telithromycin, ABT-773), novel streptogramins and novel Β-lactamase inhibitors, bacterial and fungal efflux pump inhibitors and novel antifungals (azasordarins, echinocandins, azoles).